Adaptive Biotechnologies struck two non‑exclusive agreements with Pfizer to license its T‑cell receptor discovery platform and TCR‑antigen mapping data for immune target discovery and AI model training. Adaptive will receive an upfront payment and is eligible for up to ~$890 million in milestones under one deal; the multi‑year data license will include upfront and potential annual fees. Adaptive said the collaboration accelerates target ID for rheumatoid arthritis and other indications.